

Ready to start planning your care? Call us at [800-525-2225](tel:800-525-2225) to make an appointment.

×



Memorial Sloan Kettering  
Cancer Center

[Make an Appointment](#)

[Back](#)

[Find a Physician, Center & Treatment](#)  
[Learn About Cancer & Treatment](#)

#### ABOUT US

[Our mission, vision & core values](#)

[Leadership](#)

[History](#)

[Inclusion & belonging](#)

[Annual report](#)

[Give to MSK](#)

#### FOR THE MEDIA



## Nai-Kong V. Cheung, MD, PhD

[Pediatric Hematologist-Oncologist](#) ([#about-me](#))



### Areas of Expertise

#### Conditions I Treat

- Pediatric cancers
- Neuroblastoma

#### My Specialties

- Pediatric cancer care
- Immunotherapy
- Pediatric bone marrow transplant

[View more expertise](#) ([#about\\_specialties](#))



[Dr. Cheung's Office Information](#) ([#contact-and-location](#))



Languages: English

## Get to Know Me

I am a pediatric oncologist at MSK Kids who specializes in immunologic approaches to diagnose and treat pediatric cancers. My main focus is the treatment of neuroblastoma, a tumor arising from primitive cells of the sympathetic nervous system which primarily affects young children.

Read more +

[What I Do at MSK](#)

I'm a pediatric hematologist-oncologist, which is a doctor who treats cancers and blood diseases in children, adolescents, and young adults.

- Enid A. Haupt Chair in Pediatric Oncology

### Areas of Expertise

#### Conditions I Treat

- Pediatric cancers
- Neuroblastoma

#### My Specialties

- Pediatric cancer care
- Immunotherapy
- Pediatric bone marrow transplant
- Pediatric cellular therapy
- Clinical trials
- Early-phase clinical trials

### Education & Honors

#### Education

- MD, Harvard Medical School
- PhD, Harvard Medical School

#### Residencies

- Pediatrics - Stanford University

#### Fellowships

- Pediatric Hematology/Oncology - Stanford University

#### Board Certifications

- Pediatrics
- Pediatric Hematology-Oncology

## Insurance Information

Understanding your insurance options is an important part of managing your cancer care. We have relationships with many common healthcare providers and plans.

Don't see your carrier or plan? [We can help you understand your coverage](#) .

If you don't have health insurance or are worried that your care may not be fully covered, our [financial assistance](#) programs may be able to help.

If you have questions about insurance, call us at [646-497-9176](tel:646-497-9176) .

## Contact and Location

Office Phone

 [646-888-2313](tel:646-888-2313)

Location

 New York, NY

[Memorial Sloan Kettering Cancer Center](#)

 1275 York Avenue  
New York, NY 10065  
[Get Directions](#)

Looking to see a doctor at a different location? [See all MSK locations](#) .

## Colleagues

Doctors at Memorial Sloan Kettering work as teams, with specialists from all different areas. This allows us to consider all your needs together, and to give you the best possible care.

[See all Pediatrics doctors](https://www.mskcc.org/doctor#:Departments=[Pediatrics]) ([https://www.mskcc.org/doctor#:Departments=\[Pediatrics\]](https://www.mskcc.org/doctor#:Departments=[Pediatrics]))

## Clinical Trials

- Clinical Trials Investigated by Dr. Cheung
- [Molecular Characterization of Neuroblastic Tumors and Clinical Outcome](#)



Find a Clinical Trial for You

Memorial Sloan Kettering's doctors and scientists are constantly developing new treatments for cancer. MSK is typically running hundreds of clinical trials at a given time.

You may be able to participate in a clinical trial even if you are new to MSK. Search our online directory to find trial information and see more about who can participate.

[Search clinical trials](https://www.mskcc.org/cancer-care/clinical-trials) (<https://www.mskcc.org/cancer-care/clinical-trials>)

## Research and Publications

## [View Dr. Cheung's Lab](#)

Santich BH, Cheal SM, Ahmed M, McDevitt MR, Yang G, Ouerfelli Q, Veach DR, Fung EK, Patel M, Vargas DB, Malik AA, Guo HF, Zanzonico PB, Monette S, Michel AO, Rudin CM, Larson SM, Cheung NK. [A Self-Assembling and DisAssembling \(SADA\) bispecific antibody \(BsAb\) platform for curative 2-step pre-targeted radioimmunotherapy](#). Clin Can Res. 2020;27(2):532-541. doi:10.1158/1078-0432.CCR-20-2150

Gundem G, Levine MF, Roberts SS, Cheung IY, Medina-Martínez JS, Feng Y, Arango-Ossa JE, Chadoutaud L, Rita M, Asimomitis G, Zhou J, You D, Bouvier N, Spitzer B, Solit DB, Dela Cruz F, LaQuaglia MP, Kushner BH, Modak S, Shukla N, Iacobuzio-Donahue CA, Kung AL, Cheung NV, Papaemmanuil E. [Clonal evolution during metastatic spread in high-risk neuroblastoma](#). Nat Genet. 2023 Jun;55(6):1022-1033. doi: 10.1038/s41588-023-01395-x.

Park JA, Espinosa-Cotton M, Guo HF, Monette S, Cheung NKV. [Targeting tumor vasculature to improve antitumor activity of T cells armed ex vivo with T cell engaging bispecific antibody](#). J Immunother Cancer 2023 Mar;11(3):e006680. doi:10.1136/jitc-2023-006680.

Chung SK, Vargas DB, Chandler CS, Katugampola S, Veach DR, McDevitt MR, Seo SH, Vaughn BA, Rinne SS, Punzalan B, Patel M, Xu H, Guo HF, Zanzonico PB, Monette S, Yang G, Ouerfelli O, Nash GM, Cercek A, Fung EK, Howell RW, Larson SM, Cheal SM, Cheung NK. [Efficacy of HER2-Targeted Intraperitoneal 225Ac  \$\alpha\$ -Pretargeted Radioimmunotherapy for Small-Volume Ovarian Peritoneal Carcinomatosis](#). J Nucl Med. 2023 Sep; 64(9):1439-1445. doi: 10.2967/jnumed.122.265095.

Cheung IY, Mauguen A, Modak S, Ragupathi G, Basu EM, Roberts SS, Kushner BH, Cheung NK. [Effect of Oral  \$\beta\$ -Glucan on Antibody Response to Ganglioside Vaccine in Patients With High-Risk Neuroblastoma: A Phase 2 Randomized Clinical Trial](#). JAMA Oncol. 2023 Feb;9(2):242-250, doi: 10.1001/jamaoncol.2022.5999

## Publications on PubMed

Visit PubMed for a full listing of Dr. Cheung's journal articles. Pubmed is an online index of research papers and other articles from the US National Library of Medicine and the National Institutes of Health.

[See all on PubMed \(http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=search&db=pubmed&term=%28cheung%20nk%20OR%20cheung%20nv%20OR%20%28cheung%20n%20AND%20Kettering%29%29%20NOT%20Rush%2](http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=search&db=pubmed&term=%28cheung%20nk%20OR%20cheung%20nv%20OR%20%28cheung%20n%20AND%20Kettering%29%29%20NOT%20Rush%2)

## Disclosures

Members of the MSK Community often work with pharmaceutical, device, biotechnology, and life sciences companies, and other organizations outside of MSK, to find safe and effective cancer treatments, to improve patient care, and to educate the health care community. These activities outside of MSK further our mission, provide productive collaborations, and promote the practical application of scientific discoveries.

MSK requires doctors, faculty members, and leaders to report ("disclose") the relationships and financial interests they have with external entities. As a commitment to transparency with our community, we make that information available to the public. Not all disclosed interests and relationships present conflicts of interest. MSK reviews all disclosed interests and relationships to assess whether a conflict of interest exists and whether formal COI management is needed.

Nai-Kong V. Cheung discloses the following relationships and financial interests:

- Abpro Inc  
Equity; Intellectual Property Rights
- Biotec Pharmacon  
Intellectual Property Rights
- Eureka Therapeutics Inc  
Equity; Professional Services and Activities
- Y-mAbs Therapeutics, Inc.  
Equity; Intellectual Property Rights; Professional Services and Activities

If you're a patient at MSK and would like more information about your doctor's external relationships, please talk with your doctor.

The information published here is a complement to other publicly reported data and is for a specific annual disclosure period. There may be differences between information on this and other public sites as a result of different reporting periods and/or the various ways relationships and financial interests are categorized by organizations that publish such data.

---

This page and data include information for a specific MSK annual disclosure period (January 1, 2024 through disclosure submission in spring 2025). This data

reflects interests that may or may not still exist. This data is updated annually.

Learn more about MSK's COI policies [here](#) . For questions regarding MSK's COI-related policies and procedures, email MSK's Compliance Office at [ecoi@mskcc.org](mailto:ecoi@mskcc.org) .

[View all disclosures \(https://www.mskcc.org/disclosures\)](https://www.mskcc.org/disclosures)

© 2026 Memorial Sloan Kettering Cancer Center